Pulmonx reported record worldwide revenue of $23.8 million for Q4 2024, a 23% increase year-over-year, and $83.8 million for the full year 2024, a 22% increase. The company also achieved a gross margin of 74% for both the quarter and the full year, and reduced its net loss compared to the previous year.
Record worldwide revenue of $23.8 million in Q4 2024, up 23% year-over-year.
Record full year 2024 worldwide revenue of $83.8 million, up 22% year-over-year.
Gross margin of 74% achieved for both Q4 and full year 2024.
Net loss improved to $13.2 million in Q4 2024 and $56.4 million for full year 2024.
Pulmonx expects full year 2025 revenue to be between $96 million and $98 million, representing 15% to 17% growth (16% to 18% on a constant currency basis), with an expected gross margin of approximately 74% and total operating expenses between $133 million and $135 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance